According to the National Family Health Survey-5 (2019–21), 24% of Indian women and 23% of Indian men are either overweight ...

BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise before the transaction is ...

Rezpeg's promising Phase 2b data makes Nektar Therapeutics a strong contender in the AD market. Click here to read an ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

The Vanguard Growth ETF ( VUG 0.85%) doesn't just beat the market -- it demolishes it. A $10,000 investment at its 2004 ...

Eli Lillys Mounjaro KwikPen gains approval in India, targeting diabetes and obesity with its dual-action formula for weight ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Lilly King Gets One More Win at Indy Summer Cup; Regan Smith Drops 56.5 100 Fly Soon-to-be retired Lilly King got one more ...

Apollo HealthCo clocked a revenue of ₹9,093 crore in FY25, growing 16% year-on-year. The platform delivered three successive ...

With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, ...

Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.